Citations 16

Teaching Neuroimag(ing): Lowering the Cost of Entry for Neurology Trainees to Learn and Use Cutting-Edge Neuroimaging Techniques to Ask Research Questions in the Clinical Setting (P2.356)

Neurology | December 7, 2023 | Volume: 86 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.86.16_supplement.p2.356

Morphometric Analysis on T1-Weighted MRI Complements Visual MRI Review in Focal Cortical Dysplasia (P4.073)

Neurology | December 7, 2023 | Volume: 88 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.88.16_supplement.p4.073

Hematopoietic stem cell transplantation: An Effective Treatment for CSF1R-related Leukoencephalopathy (2069)

Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.96.15_supplement.2069

Complementary and alternative medicine in an outpatient pediatric neurology clinic: Prevalence of use and attitudes toward CAM and prescription medications (S35.009)

Neurology | December 6, 2023 | Volume: 84 | Issue: 14_supplement | Pages: No page available

10.1212/wnl.84.14_supplement.s35.009

Reply to “Prophylactic Allogeneic Hematopoietic Stem Cell Therapy for CSF1R‐Related Leukoencephalopathy”

Movement Disorders | May 19, 2022 | Volume: 37 | Issue: 5 | Pages: 1109-1110

10.1002/mds.29018 | PMID 35587622

Case 10: Large Skin Defect of the Trunk Noted at Birth

Challenging Cases in Neonatology | November 8, 2021 | Volume: No volume available | Issue: No issue available | Pages: 61-67

10.1542/9781610021418-part02-case_10

Treatment of CSF1R‐Related Leukoencephalopathy: Breaking New Ground

Movement Disorders | July 30, 2021 | Volume: 36 | Issue: 12 | Pages: 2901-2909

10.1002/mds.28734 | PMID 34329526

AbstractBackgroundColony‐stimulating factor‐1 receptor (CSF1R)‐related leukoencephalopathy is a rapidly progressive neurodegenerative disease for which there is currently no cure. Hematopoietic stem cell transplantation (HSCT) has been proposed as a disease‐modifying treatment.ObjectiveThe objective of this study was to determine the effect of HSCT on disease progression.MethodsWe collected all available clinical data from a cohort of 7 patients with CSF1R‐related leukoencephalopathy who underwent HSCT at our institutions. Clinical data included detailed neurological examination by a board‐certified neurologist, serial cognitive screens, formal neuropsychological evaluations, and serial brain magnetic resonance imaging (MRI).ResultsOur patients had an average disease duration of 27.6 months at the time of transplant, and we have 87 months of total posttransplant follow‐up time (median, 11; range, 2–27). One patient died in the periprocedural period. The remaining patients showed a variable response to treatment, with 6 of 7 patients trending toward stabilization on motor examination, cognitive scores, and/or MRI abnormalities, especially with white matter lesion burden.ConclusionsThis is the largest series of patients with CSF1R‐related leukoencephalopathy receiving HSCT. We conclude that HSCT can stabilize the disease in some patients. Variability in patient responsiveness suggests that measures of disease heterogeneity and severity need to be considered when evaluating a patient's candidacy for transplant. HSCT appears to be the first disease‐modifying therapy for CSF1R‐related leukoencephalopathy. This milestone may serve as a foothold toward better understanding the disease's pathomechanism, thus providing new opportunities for better disease‐specific therapies. © 2021 International Parkinson and Movement Disorder Society
Segmentation errors and intertest reliability in automated and manually traced hippocampal volumes

Annals of Clinical and Translational Neurology | September 6, 2019 | Volume: 6 | Issue: 9 | Pages: 1807-1814

10.1002/acn3.50885 | PMID 31489797

AbstractObjectiveTo rigorously compare automated atlas‐based and manual tracing hippocampal segmentation for accuracy, repeatability, and clinical acceptability given a relevant range of imaging abnormalities in clinical epilepsy.MethodsForty‐nine patients with hippocampal asymmetry were identified from our institutional radiology database, including two patients with significant anatomic deformations. Manual hippocampal tracing was performed by experienced technologists on 3T MPRAGE images, measuring hippocampal volume up to the tectal plate, excluding the hippocampal tail. The same images were processed using NeuroQuant and FreeSurfer software. Ten subjects underwent repeated manual hippocampal tracings by two additional technologists blinded to previous results to evaluate consistency. Ten patients with two clinical MRI studies had volume measurements repeated using NeuroQuant and FreeSurfer.ResultsFreeSurfer raw volumes were significantly lower than NeuroQuant (P < 0.001, right and left), and hippocampal asymmetry estimates were lower for both automatic methods than manual tracing (P < 0.0001). Differences remained significant after scaling volumes to age, gender, and scanner matched normative percentiles. Volume reproducibility was fair (0.4–0.59) for manual tracing, and excellent (>0.75) for both automated methods. Asymmetry index reproducibility was excellent (>0.75) for manual tracing and FreeSurfer segmentation and fair (0.4–0.59) for NeuroQuant segmentation. Both automatic segmentation methods failed on the two cases with anatomic deformations. Segmentation errors were visually identified in 25 NeuroQuant and 27 FreeSurfer segmentations, and nine (18%) NeuroQuant and six (12%) FreeSurfer errors were judged clinically significant.InterpretationAutomated hippocampal volumes are more reproducible than hand‐traced hippocampal volumes. However, these methods fail in some cases, and significant segmentation errors can occur.
Spatial variation in high-frequency oscillation rates and amplitudes in intracranial EEG

Neurology | January 24, 2018 | Volume: 90 | Issue: 8 | Pages: No page available

10.1212/wnl.0000000000004998 | PMID 29367441

Clinical Reasoning: An unusual cause of indeterminate spells

Neurology | December 5, 2016 | Volume: 87 | Issue: 23 | Pages: No page available

10.1212/wnl.0000000000003403 | PMID 27920289